These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6684770)

  • 1. Effects of electroconvulsive shock on monoaminergic systems in the rat brain. Thesis.
    Wielosz M
    Pol J Pharmacol Pharm; 1983; 35(2):127-30. PubMed ID: 6684770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role of some central neurotransmitter systems in the mechanism of electroconvulsive shock action.
    Kleinrok Z; Wielosz M
    Pol J Pharmacol Pharm; 1985; 37(6):745-52. PubMed ID: 3008135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of electroconvulsive shock on central GABA-ergic mechanisms.
    Wielosz M; Stelmasiak M; Ossowska G; Kleinrok Z
    Pol J Pharmacol Pharm; 1985; 37(2):113-22. PubMed ID: 2995953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electroconvulsive shock and neurotransmitter receptors: implications for mechanism of action and adverse effects of electroconvulsive therapy.
    Lerer B
    Biol Psychiatry; 1984 Mar; 19(3):361-83. PubMed ID: 6144329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of electroconvulsive shock seizures on behaviour induced by dopaminergic agonists and on immobility in the Porsolt test.
    Zarrindast MR; Sahebgharani M; Burnham WM
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):509-14. PubMed ID: 15589391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immobilization stress modifies locomotor response to catecholamine receptor agonists in rats.
    Zebrowska-Lupina I; Stelmasiak M; Porowska A; Pietrasiewicz T
    Pol J Pharmacol Pharm; 1988; 40(5):441-50. PubMed ID: 3253715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some central effects of angiotensin II. Interactions with dopaminergic transmission.
    Georgiev V; György L; Getova D; Markovska V
    Acta Physiol Pharmacol Bulg; 1985; 11(4):19-26. PubMed ID: 3012944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central action of glaucine in rodents.
    Jagiełło-Wójtowicz E; Kleinrok Z; Jusiak L; Matuszek B; Daniłoś J; Chodakowska A
    Acta Pol Pharm; 1994; 51(2):179-84. PubMed ID: 7863789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central action of adrenaline.
    Jagiełło-Wójtowicz E
    Acta Physiol Pol; 1981; 32(2):169-80. PubMed ID: 7196677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic stimulation of the brain in animal depression models responsive to ECS.
    Belmaker RH; Grisaru N
    J ECT; 1998 Sep; 14(3):194-205. PubMed ID: 9773358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central action of phenylethylamine in rats.
    Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1981; 33(1):59-71. PubMed ID: 7196039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation.
    Levant B; Radel JD; Carlson SE
    Behav Brain Res; 2004 Jun; 152(1):49-57. PubMed ID: 15135968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central action of narcotic analgesics. VIII. The effect of dopaminergic stimulants on the action of analgesics in rats.
    Malec D; Langwiński R
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):273-82. PubMed ID: 6119681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat.
    Kostowski W; Gajewska S; Bidzinski A; Hauptman M
    Pharmacol Biochem Behav; 1976 Jul; 5(1):15-7. PubMed ID: 1033561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of antineoplaston A5 on the central dopaminergic structures.
    Juszkiewicz M; Chodkowska A; Burzynski SR; Feldo M; Majewska B; Kleinrok Z
    Drugs Exp Clin Res; 1994; 20(4):161-7. PubMed ID: 7813388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central effects of angiotensin II, its fragment and analogues.
    Georgiev VP; Klousha VE; Petkov VD; Markovska VL; Svirskis SV; Mountsinietse RK; Anouans ZE
    Acta Physiol Pharmacol Bulg; 1984; 10(4):36-43. PubMed ID: 6085530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain transcription factor gene expression, neurotransmitter levels, and novelty response behaviors: alterations during rat amphetamine withdrawal and following chronic injection stress.
    Persico AM; Schindler CW; Zaczek R; Brannock MT; Uhl GR
    Synapse; 1995 Mar; 19(3):212-27. PubMed ID: 7784961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased sensitivity to serotonergic agonists after repeated electroconvulsive shock in rats.
    Wielosz M
    Pharmacol Biochem Behav; 1985 May; 22(5):683-7. PubMed ID: 2989938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of amphetamine and apomorphine on brain monoamines and behaviour in the immature and young adult rat.
    Lal S; Feldmüller F
    Arch Int Pharmacodyn Ther; 1975 Dec; 218(2):239-51. PubMed ID: 1212022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.